JRCT ID: jRCT1030230621
Registered date:07/02/2024
PRADO study
Basic Information
Recruitment status | Pending |
---|---|
Health condition(s) or Problem(s) studied | Generalized Anxiety Disorder |
Date of first enrollment | 26/02/2024 |
Target sample size | 400 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | To estimate the prevalence of patients diagnosed with Generalized Anxiety Disorder based on DSM-5 diagnostic criteria, which is confirmed by SCID. |
---|---|
Secondary Outcome | -To evaluate patient health, QoL and functional status related scores using EuroQoL 5-dimension 5 Level (EQ-5D-5L), Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), Sheehan Disability Scale (SDISS), GAD-7, Adverse Childhood Experiences(ACE) calculator and K6. Also, Generalized Anxiety Disorder patient severity of illness will be assessed using the Clinical Global Impression Severity Scale (CGI-S). -To estimate the prevalence of patients with primary diagnosis of Generalized Anxiety Disorder based on the DSM-5 diagnostic criteria, which is confirmed by SCID. -To estimate the prevalence of patients diagnosed with Generalized Anxiety Disorder by ICD-10 diagnostic category diagnosed prior to this study. -The percentage of psychiatric disorders diagnosed other than Generalized Anxiety Disorder by SCID. -The percentage of psychiatric disorders comorbid with Generalized Anxiety Disorder by SCID. -The percentage of diagnostic agreement with the GAD-7 total score. -The percentage of diagnostic agreement with the K6 total score. -To determine the factors (variables: age, gender, family history, treatment history, medical history, disease name according to ICD-10 diagnosed prior to study participation, etc.) associated with Generalized Anxiety Disorder. -The validity of the diagnosis of Generalized Anxiety Disorder by GAD-7 and K6 in comparison to the diagnosis by SCID. |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | < 80age old |
Gender | Both |
Include criteria | Patients fulfilling all the following criteria will be enrolled in the study: 1. Patients aged more than or equal to 18 years to less than 80 years at the time of signing the informed consent form. 2. Patients who are outpatients at a psychiatrist department except for the first visit. 3. Patients with a principal diagnosis of ICD-10 Code F30-F39 mood (affective) disorders or F40-F4 neurotic, stress-related, and somatoform disorders. 4. Patients with written consent and are willing to participate in the study |
Exclude criteria | Ptients will be excluded from the study if any of the following criteria apply: 1. Participants who meet the following based on the applicable ICD-10 category. a. Patients with mental and behavioral disorders due to psychoactive substance use or diagnosed as addictive within 12-months prior to the start of the study. b. Patients with a current or past medical history of schizophrenia, delusional disorder, or other psychotic disorders. c. Patients currently having dementia. d. Patients with mood disorder or anxiety disorder due to known physiological conditions. 2. Patients with a history of convulsive disease other than single febrile seizures in childhood. 3. Patients judged to be at risk of suicide by the investigator. 4. Patients who are considered inappropriate to participate in the study by the investigator |
Related Information
Primary Sponsor | Nomoto Keisuke |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Viatris Pharmaceuticals Japan Inc. |
Secondary ID(s) |
Contact
Public contact | |
Name | Misa Arata |
Address | Keikyu Dai-1 Building 4-10-18 Takanawa, Minato-ku, Tokyo Tokyo Japan 108-0074 |
Telephone | +81-80-3598-2472 |
Misa.arata@iqvia.com | |
Affiliation | IQVIA Services Japan G.K. |
Scientific contact | |
Name | Keisuke Nomoto |
Address | Holland Hills Mori Tower 5-11-2 Toranomon, Minato-ku, Tokyo Tokyo Japan 105-0001 |
Telephone | +81-3-5656-0400 |
Keisuke.Nomoto@viatris.com | |
Affiliation | Viatris Pharmaceuticals Japan Inc. |